- Home
- BANX vs CGTX Comparison
BANX vs CGTX Comparison
Compare BANX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- CGTX
- Stock Information
- Founded
- BANX 2013
- CGTX 2007
- Country
- BANX United States
- CGTX United States
- Employees
- BANX N/A
- CGTX N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- CGTX Health Care
- Exchange
- BANX Nasdaq
- CGTX Nasdaq
- Market Cap
- BANX 149.8M
- CGTX 158.8M
- IPO Year
- BANX N/A
- CGTX 2021
- Fundamental
- Price
- BANX $21.42
- CGTX $1.66
- Analyst Decision
- BANX
- CGTX Strong Buy
- Analyst Count
- BANX 0
- CGTX 4
- Target Price
- BANX N/A
- CGTX $2.88
- AVG Volume (30 Days)
- BANX 23.4K
- CGTX 1.0M
- Earning Date
- BANX 06-17-2025
- CGTX 11-06-2025
- Dividend Yield
- BANX 9.66%
- CGTX N/A
- EPS Growth
- BANX N/A
- CGTX N/A
- EPS
- BANX 2.35
- CGTX N/A
- Revenue
- BANX $29,467,794.00
- CGTX N/A
- Revenue This Year
- BANX N/A
- CGTX N/A
- Revenue Next Year
- BANX N/A
- CGTX N/A
- P/E Ratio
- BANX $8.88
- CGTX N/A
- Revenue Growth
- BANX 2.73
- CGTX N/A
- 52 Week Low
- BANX $17.99
- CGTX $0.22
- 52 Week High
- BANX $21.67
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- BANX 57.96
- CGTX 53.76
- Support Level
- BANX $21.03
- CGTX $1.30
- Resistance Level
- BANX $21.75
- CGTX $1.55
- Average True Range (ATR)
- BANX 0.34
- CGTX 0.14
- MACD
- BANX 0.06
- CGTX -0.00
- Stochastic Oscillator
- BANX 96.52
- CGTX 70.11
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.